S-1: GT Biopharma Registers 22.6M Shares for Resale

GT Biopharma, a clinical-stage biopharmaceutical company, filed an S-1 registration statement for the resale of 22.6 million shares of common stock by existing selling stockholders, while facing Nasdaq delisting risk and going concern doubts.

Summary

• GT Biopharma, Inc. (GTBP) filed an S-1 registration statement for the resale of up to 22,686,349 shares of common stock by named selling stockholders.
• The shares registered for resale consist of 11,257,949 shares issuable upon Series L Preferred Stock conversion, 11,257,949 shares issuable upon vested warrant exercise, and 170,451 dividend shares.
• The company will not receive any proceeds from the sale of these shares by the selling stockholders, but may receive proceeds from the cash exercise of outstanding Vesting Warrants.
• GT Biopharma is a clinical-stage biopharmaceutical company focused on developing immuno-oncology products using its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms.
• The company received a Nasdaq non-compliance letter on November 20, 2025, for failing to meet the $1 minimum bid price requirement, with a compliance period until May 19, 2026. The closing price on January 20, 2026, was $0.72 per share.
• Management has raised substantial doubt about the company's ability to continue as a going concern, stating that existing cash resources may not be sufficient to fund operations for one year without additional financing.
• As of January 12, 2026, there were 26,652,194 shares of Common Stock outstanding, with warrants for up to 50,166,927 additional shares (weighted average exercise price $0.93) and options for up to 597,550 additional shares (weighted average exercise price $4.23).

Sentiment

Score: 3

Explanation: The filing highlights significant financial and operational challenges, including a going concern warning, Nasdaq delisting risk, and a continuous need for capital. While the company has proprietary technology, these severe risks overshadow any potential positives, indicating a highly precarious financial position.

Positives

• Proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms are being developed for immuno-oncology products.
• Preclinical data suggests TriKE platforms activating endogenous NK cells may be safer than T-cell immunotherapy, with less cytokine release syndrome (CRS) and fewer neurological complications.
• The TriKE platform is scalable and aims to produce investigational new drug (IND) ready moieties in a timely manner.
• Exercise of Greenshoe Rights to date generated gross proceeds of $7.55 million for working capital and general corporate purposes.

Negatives

• The company will not receive any proceeds from the sale of the 22,686,349 shares offered by the selling stockholders in this registration.
• Common Stock is not in compliance with Nasdaq's $1 minimum bid price requirement, trading at $0.72 per share on January 20, 2026, and faces potential delisting if compliance is not regained by May 19, 2026.
• Management has raised substantial doubt about the company's ability to continue as a going concern, indicating insufficient cash resources for the next year without additional financing.
• Investment in the company's securities involves a high degree of risk, including potential for significant dilution from outstanding warrants and options (50,166,927 warrants and 597,550 options).
• The company's Common Stock may be deemed a low-priced "penny stock," subjecting it to marketability restrictions and making it difficult for broker-dealers to recommend.
• There is a limited public market for the Common Stock, and the trading price may be highly volatile.
• The company does not intend to pay dividends on its Common Stock in the foreseeable future.

Risks

• A limited public market for Common Stock exists, and the trading price may be volatile and subject to wide fluctuations.
• Outstanding warrants for up to 50,166,927 shares and options for up to 597,550 shares may affect the market price and will have a dilutive effect on current stockholders' ownership upon exercise.
• Common Stock may be deemed a low-priced "penny stock," restricting broker-dealers' ability to sell and affecting marketability and price.
• Lack of research coverage by securities or industry analysts could negatively affect stock price and trading volume.
• Anti-takeover provisions in Delaware law, the Charter, and Bylaws may limit the ability of another party to acquire the company, potentially causing the stock price to decline.
• No current or foreseeable intention to pay dividends on Common Stock, limiting investor returns to stock price appreciation.
• Purchasers in this offering will experience immediate and substantial dilution in the book value of their investment.
• The company needs additional capital to conduct operations and develop products, and its ability to obtain necessary funding on acceptable terms is uncertain, which could materially adversely affect business prospects and ability to continue as a going concern.
• Risk of delisting from Nasdaq due to non-compliance with the $1 minimum bid price requirement, which would adversely affect liquidity and market price.
• Substantial doubt exists about the company's ability to continue as a going concern, as existing cash resources are believed to be insufficient to fund operations for one year without additional financing.

Future Outlook

The company intends to continue developing and commercializing its proprietary TriKE and Dual Targeting TriKE immuno-oncology platforms. However, its ability to fund anticipated operations beyond one year is uncertain without securing additional financing. The company is also actively monitoring its stock price and evaluating options to regain compliance with Nasdaq's minimum bid price requirement to avoid delisting.

Management Comments

• "We believe our TriKE and Dual Targeting TriKE platforms that activate endogenous NK cells are potentially safer than T-cell immunotherapy because there is less cytokine release syndrome (CRS) and fewer neurological complications."
• "We are using our TriKE platform with the intent to bring to market immuno-oncology products that can treat a range of hematologic malignancies, solid tumors, and potentially autoimmune disorders."
• "We believe our TriKEs may have the ability, if approved for marketing, to be used as both monotherapy and in combination with other standard-of-care therapies."
• "We intend to use the net proceeds from such exercise of Greenshoe Rights for working capital and general corporate purposes."
• "The Company continues to monitor the closing bid price of the Common Stock and assess its available options to regain compliance with the Minimum Bid Price Requirement and continue listing on Nasdaq."
• "We believe if we are unable to obtain additional financing, existing cash resources will not be sufficient to enable us to fund the anticipated level of our operations through one year from the date the financial statements included in our annual report on Form 10-K for the year ended December 31, 2024 were issued."

Industry Context

GT Biopharma operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically within immuno-oncology. Its focus on Natural Killer (NK) cell engager technology platforms (TriKE and Dual Targeting TriKE) positions it in a rapidly evolving area of cancer therapy, aiming to offer potentially safer alternatives to T-cell immunotherapies. The success of its proprietary platforms will depend on clinical development, regulatory approvals, and market adoption in a landscape dominated by both large pharmaceutical companies and numerous smaller biotech firms.

Corporate Governance

Stakeholder Impact

• Shareholders face significant dilution risk from the large number of outstanding warrants and options, potential stock price volatility, and the risk of delisting from Nasdaq. Returns are limited to stock price appreciation as no dividends are anticipated.
• Potential Investors considering the company's securities face a high degree of risk, including the "penny stock" classification which may limit marketability and the ability of broker-dealers to recommend the stock.
• The company's ability to continue operations and develop product candidates is contingent on securing additional financing, which is uncertain, directly impacting employees, suppliers, and future business prospects.

Next Steps

• Selling stockholders may offer and sell up to 22,686,349 shares of Common Stock from time to time.
• The company must regain compliance with Nasdaq's $1 minimum bid price requirement by May 19, 2026, or face potential delisting.
• The company needs to secure additional financing to fund its operations and product development initiatives.
• Continue preclinical development and clinical trials for its TriKE and Dual Targeting TriKE platforms.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a 'going concern' warning from management and its independent auditor, indicating a high probability of insufficient funds to sustain operations for the next year. Furthermore, the stock is non-compliant with Nasdaq's minimum bid price requirement and faces potential delisting, which would significantly impair liquidity and investor confidence. While the company possesses proprietary technology, the immediate and substantial financial and operational risks, coupled with significant potential dilution from outstanding warrants and options, make the stock a high-risk investment with a strong likelihood of further value erosion. The current S-1 filing is for resale by existing stockholders, meaning no new capital is being raised by the company from this specific offering, further exacerbating its liquidity concerns.

Keywords

Biopharma, Immuno-oncology, TriKE, Dual Targeting TriKE, NK cells, Cancer therapy, SEC filing, S-1, Nasdaq, Delisting risk, Going concern, Private placement, Warrants, Preferred stock, Dilution, Biotechnology